Study of tegavivint plus zanzalintinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two new drugs together for people with advanced liver cancer that has not responded to other treatments or who cannot take standard immunotherapies. The combination aims to target specific genetic changes in the tumor to slow or stop its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a confirmed diagnosis of hepatocellular carcinoma (HCC), a type of liver cancer.
- Your cancer is at an advanced stage (BCLC stage C or some stage B) and is not suitable for local treatments like surgery or ablation.
- Your liver function is relatively good (Child-Pugh class A).
- Your tumor or blood shows a specific genetic change in the Wnt pathway (like CTNNB1, AXIN1, CREBBP, or APC).
- You have tried at least one systemic therapy (like immunotherapy) that didn't work or you are not eligible for immunotherapy.
- You have measurable disease on a CT or MRI scan.
- Your overall health status is good (ECOG score 0 or 1).
- Your blood counts and kidney/liver function meet certain levels (e.g., adequate platelets, hemoglobin, kidney function).
- You have not been treated with a VEGFR-TKI (a type of targeted therapy) or tegavivint before.
- You do not have certain serious conditions like uncontrolled bleeding, major heart problems, or active infections (except controlled hepatitis B or past hepatitis C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.